This in comparison with Rs 150 per dose it fees the central authorities for the present provides.
We at @SerumInstIndia have for the previous 5 a long time been on the forefront of supplying vaccines and saving lives g… https://t.co/VFURmdG28A
— SerumInstituteIndia (@SerumInstIndia) 1619259243000
“There was an inaccurate comparison done between the global prices of the vaccine with India,” SII stated. “Covisheld is the most affordable Covid-19 vaccine available in the market today.”
The initial worth, it stated, was “kept low globally as it was based on advance funding given by those countries for at risk vaccine manufacturing.”
“The initial supply price of Covishield for all government immunization programme, including India, has been the lowest,” it stated.
“The current situation is extremely dire, the virus is constantly mutating while the public remains at risk. Identifying the uncertainty, we have to ensure sustainability as we must be able to invest in scaling up and expanding our capacity to fight the pandemic and save lives.”
SII went on so as to add that solely a restricted portion of SII’s quantity will probably be bought to personal hospitals at Rs 600 per dose.
“The price of the vaccine is still lower than a lot of other medical treatment and essentials required to treat COVID-19 and other life threatening diseases,” it added.
#Serum #Institute #defends #vaccine #pricing #initial #rates #based #advance #funding